Pre-made Enoticumab benchmark antibody ( Whole mAb, anti-DLL4 therapeutic antibody, Anti-AOS6/delta4/hdelta2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Enoticumab biosimilar, Whole mAb, Anti-DLL4 Antibody: Anti-AOS6/delta4/hdelta2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Enoticumab (REGN421, INN) is a human monoclonal antibody that binds to DLL4. It acts as an immunomodulator.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-186-1mg	1mg	3090
GMP-Bios-ab-186-10mg	10mg	Inquiry
GMP-Bios-ab-186-100mg	100mg	Inquiry
GMP-Bios-ab-186-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Enoticumab biosimilar, Whole mAb, Anti-DLL4 Antibody: Anti-AOS6/delta4/hdelta2 therapeutic antibody
INN Name	Enoticumab
Target	DLL4
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2012
Year Recommended	2013
Companies	Regeneron Pharmaceuticals;Sanofi
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Solid tumours
Development Tech	VelocImmune Mouse